NZ538223A - Calcium receptor modulating compound and use thereof - Google Patents

Calcium receptor modulating compound and use thereof

Info

Publication number
NZ538223A
NZ538223A NZ538223A NZ53822303A NZ538223A NZ 538223 A NZ538223 A NZ 538223A NZ 538223 A NZ538223 A NZ 538223A NZ 53822303 A NZ53822303 A NZ 53822303A NZ 538223 A NZ538223 A NZ 538223A
Authority
NZ
New Zealand
Prior art keywords
group
substituted
alkyl
optionally substituted
pyrimidine
Prior art date
Application number
NZ538223A
Other languages
English (en)
Inventor
Tsuneo Yasuma
Akira Mori
Masahiro Kawase
Hiroyuki Kimura
Masato Yoshida
Albert Charles Gyorkos
Scott Alan Pratt
Christopher Peter Corrette
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of NZ538223A publication Critical patent/NZ538223A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/14Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
NZ538223A 2002-08-26 2003-08-21 Calcium receptor modulating compound and use thereof NZ538223A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40601202P 2002-08-26 2002-08-26
US46612903P 2003-04-28 2003-04-28
PCT/US2003/026317 WO2004017908A2 (en) 2002-08-26 2003-08-21 Calcium receptor modulating compound and use thereof

Publications (1)

Publication Number Publication Date
NZ538223A true NZ538223A (en) 2008-03-28

Family

ID=31949909

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ538223A NZ538223A (en) 2002-08-26 2003-08-21 Calcium receptor modulating compound and use thereof

Country Status (12)

Country Link
US (3) US7514441B2 (https=)
EP (1) EP1572113B1 (https=)
JP (1) JP4494205B2 (https=)
KR (1) KR101050700B1 (https=)
AU (1) AU2003265585B2 (https=)
BR (1) BRPI0313880B8 (https=)
CA (1) CA2494700C (https=)
ES (1) ES2635838T3 (https=)
NO (1) NO332991B1 (https=)
NZ (1) NZ538223A (https=)
PL (1) PL382706A1 (https=)
WO (1) WO2004017908A2 (https=)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101050700B1 (ko) * 2002-08-26 2011-07-20 다케다 야쿠힌 고교 가부시키가이샤 칼슘 수용체 조절 화합물 및 이의 용도
US7453002B2 (en) * 2004-06-15 2008-11-18 Bristol-Myers Squibb Company Five-membered heterocycles useful as serine protease inhibitors
US7361789B1 (en) 2004-07-28 2008-04-22 Amgen Inc. Dihydronaphthalene compounds, compositions, uses thereof, and methods for synthesis
US7790770B2 (en) 2005-11-23 2010-09-07 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
WO2007102531A1 (ja) * 2006-03-08 2007-09-13 Takeda Pharmaceutical Company Limited 併用薬
CN101437490A (zh) 2006-04-20 2009-05-20 安美基公司 稳定乳液配方
EP1975165A1 (de) 2007-03-27 2008-10-01 Boehringer Ingelheim Pharma GmbH & Co. KG Substituierte Pyrrolidinamide, deren Herstellung und deren Verwendung als Arzneimittel
CA2681582C (en) 2007-03-30 2015-07-14 Amgen Inc. Methods of treating bowel disorders
WO2008139947A1 (ja) * 2007-05-08 2008-11-20 Ajinomoto Co., Inc. 下痢の予防又は治療剤
US8642597B2 (en) 2007-08-27 2014-02-04 Basf Se Pyrazole compounds for controlling invertebrate pests
US8586571B2 (en) * 2007-10-18 2013-11-19 Takeda Pharmaceutical Company Limited Heterocyclic compound
RU2502730C2 (ru) 2008-06-05 2013-12-27 Асахи Касеи Фарма Корпорейшн Сульфонамидные соединения и их применение
CN102066321A (zh) * 2008-06-16 2011-05-18 弗·哈夫曼-拉罗切有限公司 作为nk2受体拮抗剂的吡咯烷衍生物
PL2342196T3 (pl) 2008-09-24 2015-12-31 Basf Se Związki pirazolowe do zwalczania szkodników będących bezkręgowcami
CN102223798A (zh) * 2008-09-24 2011-10-19 巴斯夫欧洲公司 用于防治无脊椎动物害虫的吡唑化合物
WO2010096115A1 (en) 2008-10-29 2010-08-26 Apath, Llc Compounds, compositions and methods for control of hepatitis c viral infections
US8318759B2 (en) * 2009-02-18 2012-11-27 Hoffmann-La Roche Inc. Pyrrolidine derivatives as NK3 receptor antagonists
WO2010104882A1 (en) 2009-03-10 2010-09-16 Amgen Inc. Methods of modulating sperm motility
WO2011003793A1 (en) 2009-07-06 2011-01-13 Basf Se Pyridazine compounds for controlling invertebrate pests
WO2011003796A1 (en) 2009-07-06 2011-01-13 Basf Se Pyridazine compounds for controlling invertebrate pests
WO2011009804A2 (en) 2009-07-24 2011-01-27 Basf Se Pyridine derivatives compounds for controlling invertebrate pests
US8883801B2 (en) 2010-08-23 2014-11-11 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
JP2014511894A (ja) * 2011-04-20 2014-05-19 グラクソ グループ リミテッド 抗結核化合物としてのテトラヒドロピラゾロ[1,5‐a]ピリミジン
JO3407B1 (ar) 2012-05-31 2019-10-20 Eisai R&D Man Co Ltd مركبات رباعي هيدرو بيرازولو بيريميدين
GB201217330D0 (en) 2012-09-28 2012-11-14 Univ Cardiff Therapeutic for treating inflammatory lung disorders
US9573954B2 (en) 2012-11-16 2017-02-21 University Health Network Pyrazolopyrimidine compounds
WO2014139326A1 (en) 2013-03-13 2014-09-18 Genentech, Inc. Pyrazolo compounds and uses thereof
HRP20170217T1 (hr) * 2013-04-25 2017-04-21 Beigene, Ltd. Fuzinirani heterociklički spojevi kao inhibitori protein kinaze
TW201602062A (zh) 2013-08-12 2016-01-16 魯賓有限公司 取代聯苯基化合物作為鈣敏感受體調節劑
EA034666B1 (ru) 2013-09-13 2020-03-04 Бейджин Свитзерланд Гмбх Антитело против pd-1 и его применение для лечения рака или вирусной инфекции и фрагмент антитела
CN106132967B (zh) 2014-03-27 2019-05-28 詹森药业有限公司 作为ros1抑制剂的化合物
EP3129376B1 (en) 2014-03-27 2018-12-26 Janssen Pharmaceutica NV Substituted 4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyrazine derivatives and 5,6,7,8-tetrahydro-4h-pyrazolo[1,5-a][1,4]diazepine derivatives as ros1 inhibitors
WO2015162538A1 (en) 2014-04-21 2015-10-29 Lupin Limited Heterocyclic compounds as calcium sensing receptor modulators for the treatment of hyperparathyroidism, chronic renal failure and chronic kidney disease
TWI726608B (zh) 2014-07-03 2021-05-01 英屬開曼群島商百濟神州有限公司 抗pd-l1抗體及其作為治療及診斷之用途
WO2017037616A1 (en) 2015-08-31 2017-03-09 Lupin Limited Arylalkylamine compounds as calcium sensing receptor modulators
EP3156405A1 (en) 2015-10-13 2017-04-19 Boehringer Ingelheim International GmbH Spirocyclic ether derivatives of pyrazolo[1,5-a]pyrimidine-3-carboxamide
BR112018007664B1 (pt) 2015-10-16 2023-12-19 Eisai R&D Management Co., Ltd Compostos antagonistas de ep4, composição compreendendo o composto e uso dos mesmos para tratar câncer
CN108601784A (zh) * 2015-12-25 2018-09-28 武田药品工业株式会社 药物
WO2017170354A1 (ja) 2016-03-28 2017-10-05 武田薬品工業株式会社 医薬
US10864203B2 (en) 2016-07-05 2020-12-15 Beigene, Ltd. Combination of a PD-1 antagonist and a RAF inhibitor for treating cancer
CA3033827A1 (en) 2016-08-16 2018-02-22 Beigene, Ltd. Crystalline form of (s)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl )-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide,preparation, and uses thereof
PT3500299T (pt) 2016-08-19 2024-02-21 Beigene Switzerland Gmbh Combinação de zanubrutinib com um anticorpo anti-cd20 ou anti-pd-1 para utilização no tratamento do cancro
CR20190157A (es) 2016-08-31 2019-08-13 Agios Pharmaceuticals Inc Inhibidores de procesos metabólicos celulares
JOP20190060A1 (ar) * 2016-09-26 2019-03-26 Chugai Pharmaceutical Co Ltd مشتق بيرازولو بيريدين له تأثير مساعد لمستقبل glp-1
US11071721B2 (en) 2016-12-02 2021-07-27 Genentech, Inc. Bicyclic amide compounds and methods of use thereof
EP3573989A4 (en) 2017-01-25 2020-11-18 Beigene, Ltd. CRYSTALLINE FORMS OF (S) -7- (1- (BUT-2-YNOYL) PIPERIDIN-4-YL) -2- (4-PHENOXYPHENYL) -4, 5, 6, 7-TETRAHY DROPYRAZOLO [1, 5-A ] PYRIMIDINE-3-CARBOXAMIDE, PREPARATION AND ASSOCIATED USES
CA3061600A1 (en) 2017-04-27 2019-10-25 Takeda Pharmaceutical Company Limited Heterocyclic compound
AU2018257332B2 (en) 2017-04-27 2021-11-04 Takeda Pharmaceutical Company Limited Heterocyclic compound
TW202515616A (zh) 2017-06-26 2025-04-16 英屬開曼群島商百濟神州有限公司 抗pd-1抗體或其抗原結合片段在製備治療用於患有肝細胞癌(hcc)之藥物的用途
US11098058B2 (en) 2017-07-14 2021-08-24 Genentech, Inc. Bicyclic ketone compounds and methods of use thereof
WO2019034009A1 (en) 2017-08-12 2019-02-21 Beigene, Ltd. BTK INHIBITOR WITH ENHANCED DOUBLE SELECTIVITY
SG11202002877RA (en) 2017-10-31 2020-04-29 Hoffmann La Roche Bicyclic sulfones and sulfoxides and methods of use thereof
JP7461104B2 (ja) * 2017-11-29 2024-04-03 中外製薬株式会社 Glp-1受容体アゴニスト作用を持つピラゾロピリジン誘導体を含有する医薬組成物
CN111801334B (zh) 2017-11-29 2023-06-09 百济神州瑞士有限责任公司 使用包含btk抑制剂的组合治疗惰性或侵袭性b-细胞淋巴瘤
CN113302193A (zh) 2019-01-11 2021-08-24 豪夫迈·罗氏有限公司 双环吡咯并三唑酮化合物及其使用方法
WO2020249001A1 (zh) 2019-06-10 2020-12-17 百济神州瑞士有限责任公司 一种含有布鲁顿氏酪氨酸激酶抑制剂的口服固体片剂及其制备方法
US11786531B1 (en) 2022-06-08 2023-10-17 Beigene Switzerland Gmbh Methods of treating B-cell proliferative disorder

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4918074A (en) * 1984-03-12 1990-04-17 Yoshitomi Pharmaceutical Industries, Ltd. Polyazaheterocycle compounds
EP0217142A3 (en) * 1985-09-30 1988-01-07 Yoshitomi Pharmaceutical Industries, Ltd. A polyazaheterocyclic compound
US4746656A (en) 1986-07-21 1988-05-24 E. R. Squibb & Sons, Inc. 1,2,4,7-tetrahydro-2-oxopyrazolo[1,5-a]pyrimidine derivatives
GB9303993D0 (en) * 1993-02-26 1993-04-14 Fujisawa Pharmaceutical Co New heterocyclic derivatives
DK1206474T3 (da) 1999-08-27 2004-10-04 Abbott Lab Sulfonylphenylpyrazolforbindelser anvendelige som cox-2-inhibitorer
EP1857443B1 (en) 2000-01-24 2012-03-28 AstraZeneca AB Therapeutic morpholino-substituted compounds
EP1368355B1 (de) * 2001-03-14 2006-06-07 Grünenthal GmbH Substituierte pyrazolo- und thiazolopyrimidine als analgetika
KR101050700B1 (ko) * 2002-08-26 2011-07-20 다케다 야쿠힌 고교 가부시키가이샤 칼슘 수용체 조절 화합물 및 이의 용도

Also Published As

Publication number Publication date
BRPI0313880B8 (pt) 2021-05-25
EP1572113A4 (en) 2006-11-22
US20060079536A1 (en) 2006-04-13
PL382706A1 (pl) 2007-11-26
WO2004017908A2 (en) 2004-03-04
NO332991B1 (no) 2013-02-11
KR20050038641A (ko) 2005-04-27
KR101050700B1 (ko) 2011-07-20
JP4494205B2 (ja) 2010-06-30
EP1572113A2 (en) 2005-09-14
BR0313880A (pt) 2007-11-06
AU2003265585A1 (en) 2004-03-11
AU2003265585B2 (en) 2008-07-03
JP2006510582A (ja) 2006-03-30
NO20051328L (no) 2005-03-15
WO2004017908A3 (en) 2006-01-05
US7514441B2 (en) 2009-04-07
CA2494700C (en) 2011-06-28
BRPI0313880B1 (pt) 2016-09-27
US20090215746A1 (en) 2009-08-27
US9447100B2 (en) 2016-09-20
US20140155416A1 (en) 2014-06-05
ES2635838T3 (es) 2017-10-05
CA2494700A1 (en) 2004-03-04
EP1572113B1 (en) 2017-05-17

Similar Documents

Publication Publication Date Title
NZ538223A (en) Calcium receptor modulating compound and use thereof
RU2696270C1 (ru) Производные тетрагидроимидазопиридина в качестве модуляторов активности tnf
DE602004007808T2 (de) Neue gamma-sekretase-inhibitoren
RU2684641C1 (ru) Производные пиразолопиридина в качестве модуляторов активности tnf
RU2683318C1 (ru) Производные имидазопиридина в качестве модуляторов активности tnf
RU2677699C1 (ru) Производные имидазотриазина в качестве модуляторов активности tnf
RU2684637C1 (ru) Производные тетрагидробензимидазола в качестве модуляторов активности tnf
RU2679609C1 (ru) Производные имидазопиридазина в качестве модуляторов активности tnf
BRPI0807014A2 (pt) Composto, pró-droga, agente farmacêutico, métodos para melhorar a resistência a insulina em um mamífero, método para a profilaxia ou o tratamento de diabetes em um mamífero, e, uso de um composto.
RU2683940C1 (ru) Производные имидазотиазола в качестве модуляторов активности tnf
SK3812002A3 (en) Pyrazolopyrimidines as therapeutic agents
RU2696275C1 (ru) Производные имидазопиридина в качестве модуляторов активности tnf
EP4423068A1 (en) Rxfp1 agonists
JP5159630B2 (ja) 縮環複素環誘導体
KR100780584B1 (ko) 티에노피리딘 유도체, 이의 제조 및 용도
AU2010272524A1 (en) Tricyclic indole-derived spiro derivatives as CRTH2 modulators
KR20000010617A (ko) 티에노피리딘 유도체 및 이의 용도

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 21 AUG 2016 BY CPA GLOBAL

Effective date: 20130704

LAPS Patent lapsed